R&D
Perspectives in viral clearance
Since the 1990s, viral clearance (VC) studies have been a critical safety step for biologic drugs.
News
AI could lead to 'golden age' of antibiotics
Generative artificial intelligence could hold the key to turning back the rising tide of antimicrobial resistance, say MIT researchers.
News
Vedanta's microbiome therapy for IBD disappoints
Vedanta's microbiome therapy for ulcerative colitis has failed a phase 2 trial and will be shelved, prompting a 20% cut in workforce.
R&D
Xenotransplantation at the brink of breakthrough: A new era ...
In a landmark procedure performed at Massachusetts General Hospital (MGH) on 25th January 2025, a 66-year-old man with end-stage renal disease (ESRD) received a genetically modif
News
More good news in Sjogren's as RemeGen trial delivers
A second new drug, RemeGen's telitacicept, has shown efficacy in a phase 3 Sjögren's syndrome trial in the space of a week.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks